Firmer look to biotech fledglings gets

The Investment Column

The fledgling biotechnology sector of the stock market has had a storming rise this year, outperforming the already healthy increase of major drugs groups. But for most of the two to three years since the majority of the companies came to market, investment in the sector has been seen as something of a casino by investors - and with good reason.

British Biotech is a case in point. Seen as one of the more serious players, with a market capitalisation now well over pounds 400m, it saw its share price plunge from 590p to 428p in February after it revealed problems with clinical trials of its then most promising drug, the anti-cancer compound batimastat. Since then the shares have soared close to 900p.

This roller-coaster ride is typical of the sector, but there are signs that it is moving onto a somewhat firmer footing, with institutions showing more serious interest in investing and the product portfolio edging towards commercial exploitation.

Last Friday's news that Chiroscience had become the first of the new biotech companies to win regulatory approval - for its painkiller dexketoprofen - was something of a milestone in this respect. The decision does not necessarily mean that other companies' products will be similarly blessed by the authorities, but it does show that the industry has the potential to move from the unquantifiable "blue sky" research stage to the creation of products that have the capacity to generate sales.

British Biotech's recovery from the February debacle is also testimony to its diversification strategy. Far from proving fatal, had it been the group's only product, batimastat's starring role has now been taken by a new oral anti-cancer drug, BB-2516. Indeed, the end of this month should see the release of data on trials of BB-2516, which could have a big effect on the share price.

Given the current level of the shares, British Bio's immediate financing needs should be assured by warrants exercisable at 525p over the turn of the year, which will raise pounds 47.5m.

Celltech, another of the better-regarded members of the sector, has also been steadily building a decent development portfolio, ranging from asthma to inflammatory bowel disorders. It has also been one of the most successful at cutting the risks associated with the sector by cultivating link-ups with big groups like Zeneca and Roche.

Even Scotia, the largest of the pack and a producer of evening primrose oil, has fought off its fringe image, with the market now getting excited about its anti-cancer compounds.

But investors should remember that profits from most of these companies are unlikely to emerge much before the next century. It would be strange if, before then, some of them did not fall by the wayside.

Start your day with The Independent, sign up for daily news emails
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Claims Administrator

£16000 - £18500 per annum: Recruitment Genius: This is an excellent opportunit...

Recruitment Genius: Senior SEO Executive

£24000 - £28000 per annum: Recruitment Genius: A Senior SEO Executive is requi...

Recruitment Genius: Online Customer Service Administrator

£16000 - £18000 per annum: Recruitment Genius: An Online customer Service Admi...

Recruitment Genius: Digital Marketing Executive

£18000 - £22000 per annum: Recruitment Genius: This global, industry leading, ...

Day In a Page

'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power
Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

The price to be paid for challenging the rule of extremists

A revolution now 'consuming its own children'
Welcome to the world of Megagames

Welcome to the world of Megagames

300 players take part in Watch the Skies! board game in London
'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

Charlotte Gainsbourg on 'Nymphomaniac'

Starring in one of the most explicit films ever
Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

Robert Fisk in Abu Dhabi

The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

Vince Cable exclusive interview

Charging fees for employment tribunals was 'a very bad move'
Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

Iwan Rheon is returning to his Welsh roots

Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
Russell Brand's interview with Ed Miliband has got everyone talking about The Trews

Everyone is talking about The Trews

Russell Brand's 'true news' videos attract millions of viewers. But today's 'Milibrand' interview introduced his resolutely amateurish style to a whole new crowd
Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

It's time for my close-up

Meet the man who films great whites for a living
Increasing numbers of homeless people in America keep their mobile phones on the streets

Homeless people keep mobile phones

A homeless person with a smartphone is a common sight in the US. And that's creating a network where the 'hobo' community can share information - and fight stigma - like never before
'Queer saint' Peter Watson left his mark on British culture by bankrolling artworld giants

'Queer saint' who bankrolled artworld giants

British culture owes a huge debt to Peter Watson, says Michael Prodger
Pushkin Prizes: Unusual exchange programme aims to bring countries together through culture

Pushkin Prizes brings countries together

Ten Scottish schoolchildren and their Russian peers attended a creative writing workshop in the Highlands this week
14 best kids' hoodies

14 best kids' hoodies

Don't get caught out by that wind on the beach. Zip them up in a lightweight top to see them through summer to autumn
Robert Fisk in Abu Dhabi: The acceptable face of the Emirates

The acceptable face of the Emirates

Has Abu Dhabi found a way to blend petrodollars with principles, asks Robert Fisk